Biosimilar Manufacturing solution center

31. A Scalable Analytical Method For Quality-Driven AAV Characterization 7/1/2026

    AEX-HPLC has emerged as a robust, GMP-compatible analytical method for accurately characterizing AAV capsid composition, enabling consistent assessment of empty, partial, and full capsids to support product quality, process development, and regulatory readiness.

32. Step Into The Future Of Chromatography Automation 7/1/2026

    As downstream processing grows more connected and complex, chromatography remains a key automation challenge. See how greater flexibility and stronger control are shaping more practical workflows.

33. Process Intensification Through Downstream Connectivity 7/1/2026

    See how downstream steps can be linked into a coordinated workflow, with practical insight into automation, equipment integration, and process control for building a more efficient strategy.

34. Solving Glycoengineering Challenges Could Begin At The Cell Line 6/26/2026

    Researchers produced a panel of platform cell lines illustrating how glycoform selection can be made experimentally visible earlier in biologics development.

35. What Biopharma Often Overlooks In A Scheduled Shutdown 6/26/2026

    Shutting down an operating biologics facility upsets systems often designed for continuous operation. One expert shares his tips for preventing unnecessary problems.

36. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

    Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

37. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

    Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

38. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

    In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

39. mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models 6/19/2026

    Repeat dosing may be essential for long-term mRNA applications. Explore safety, immune-response, and efficacy findings from multiple LNP administrations, including a nine-dose evaluation over six months.

40. Discover A System That Can Be Used With Various Cell Culture Media 6/19/2026

    Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.